Apport de l'observation satellitaire pour la prévision du temps

Cet article illustre divers apports des observations satellitaires à la prévision du temps. Les techniques permettant d'extraire, à partir des mesures des instruments embarqués, des informations quantitatives sur les principaux paramètres météorologiques (température, contenu en vapeur d'eau, composantes du vent) sont succinctement décrites. Les progrès réalisés depuis une vingtaine d'années pour utiliser de manière plus efficace les observations satellitaires en vue d'initialiser les modèles de prévision numérique du temps sont ensuite présentés. Plusieurs produits développés pour l'aide à la prévision immédiate (jusqu'à 6 heures d'échéance) sont introduits en mettant l'accent sur l'outil RDT (Rapid Developing Thunderstorm) qui permet d'identifier les phases de croissance des cellules convectives pouvant donner naissance à des orages violents.The paper describes various applications of satellite observations for weather prediction. Techniques allowing the extraction of quantitative information on the main meteorological quantities (temperature, water vapour, wind components) from the measurements of onboard instruments are briefly presented. Progress achieved over the last twenty years in order to use more efficiently satellite observations for the initialization of numerical weather prediction models is summarized. Finally, several products developed for nowcasting applications (up to 6 hour forecast range) are introduced with an emphasis on the « RDT » (Rapid Developing Thunderstorm) that allows to identify the growing phase of convective cells that could lead to severe thunderstorms

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

International audienceBackground: In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). PRECONNECT was designed to further characterise safety and clinical use of trifluridine/tipiracil.Methods: In this ongoing, international, multicentre, open-label trial, patients with pretreated mCRC received oral trifluridine/tipiracil 35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle. The primary endpoint was safety; secondary endpoints included PFS and quality of life (QoL).Results: 793 patients (median age 62 years) from 13 countries received trifluridine/tipiracil for a median of 2.84 months (IQR 2.64). Adverse events (AEs) were experienced by 96.7%; the most common (≥20% of patients) were neutropaenia, asthenia/fatigue, nausea, anaemia and diarrhoea. Grade ≥3 AEs occurred in 73.9% of patients, with the most common being neutropaenia (39.1% of patients), anaemia (9.8%) and asthenia/fatigue (5.0%). Median PFS was 2.8 months (95% CI 2.7 to 2.9). Median time to Eastern Cooperative Oncology Group performance status deterioration (≥2) was 8.9 months (range 0.03-14.72). There was no clinically relevant change from baseline in QoL.Conclusions: PRECONNECT showed consistent results with the previously demonstrated safety and efficacy profile of trifluridine/tipiracil, with no new safety concerns identified. QoL was maintained during treatment

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

BACKGROUND: In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). PRECONNECT was designed to further characterise safety and clinical use of trifluridine/tipiracil. METHODS: In this ongoing, international, multicentre, open-label trial, patients with pretreated mCRC received oral trifluridine/tipiracil 35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle. The primary endpoint was safety; secondary endpoints included PFS and quality of life (QoL). RESULTS: 793 patients (median age 62 years) from 13 countries received trifluridine/tipiracil for a median of 2.84 months (IQR 2.64). Adverse events (AEs) were experienced by 96.7%; the most common (≥20% of patients) were neutropaenia, asthenia/fatigue, nausea, anaemia and diarrhoea. Grade ≥3 AEs occurred in 73.9% of patients, with the most common being neutropaenia (39.1% of patients), anaemia (9.8%) and asthenia/fatigue (5.0%). Median PFS was 2.8 months (95% CI 2.7 to 2.9). Median time to Eastern Cooperative Oncology Group performance status deterioration (≥2) was 8.9 months (range 0.03-14.72). There was no clinically relevant change from baseline in QoL. CONCLUSIONS: PRECONNECT showed consistent results with the previously demonstrated safety and efficacy profile of trifluridine/tipiracil, with no new safety concerns identified. QoL was maintained during treatment. TRIAL REGISTRATION NUMBER: NCT03306394.status: publishe

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

Background In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). PRECONNECT was designed to further characterise safety and clinical use of trifluridine/tipiracil. Methods In this ongoing, international, multicentre, open-label trial, patients with pretreated mCRC received oral trifluridine/tipiracil 35 mg/m(2) twice daily on days 1-5 and 8-12 of each 28-day cycle. The primary endpoint was safety; secondary endpoints included PFS and quality of life (QoL). Results 793 patients (median age 62 years) from 13 countries received trifluridine/tipiracil for a median of 2.84 months (IQR 2.64). Adverse events (AEs) were experienced by 96.7\%; the most common (>= 20\% of patients) were neutropaenia, asthenia/fatigue, nausea, anaemia and diarrhoea. Grade >= 3 AEs occurred in 73.9\% of patients, with the most common being neutropaenia (39.1\% of patients), anaemia (9.8\%) and asthenia/fatigue (5.0\%). Median PFS was 2.8 months (95\% CI 2.7 to 2.9). Median time to Eastern Cooperative Oncology Group performance status deterioration (>= 2) was 8.9 months (range 0.03-14.72). There was no clinically relevant change from baseline in QoL. Conclusions PRECONNECT showed consistent results with the previously demonstrated safety and efficacy profile of trifluridine/tipiracil, with no new safety concerns identified. QoL was maintained during treatment